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Abstract: By virtue of the rapid development of nuclear medicine technologies, pharmacoeconomics shall occupy one of 
the key roles in assessing the applicability of one or another nuclear medicine’s methods in clinical practice. Based on 
existing evidence, application of the 153Sm-EDTMP and 89SrCl2 S is an economically feasible approach to treat painful 
bone metastases. Comparing to existing radiopharmaceutical agents intended for therapy of painful bone metastases, 
radiopharmaceutical agents that have been developed on the basis of generator-produced radionuclide Rhenium 188 
(e.g. 188Re-HEDP, 188Re-zoledronic acid), allow to believe in the explicit economic advantage in future when 
implementing into clinical practice. 
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INTRODUCTION 
According to the World Health Organization (WHO), 
cancer is one of the leading causes of death in the 
whole World -In 2012, an estimated 8.2 million (mln) 
people died from cancer. Each year, most cancer-
induced deaths are caused by malignant neoplasms of 
the lungs, stomach, liver, colon and mammary gland. 
Over 60% of new cancer cases are registered in 
countries of Africa, Asia, Central and South America. 
70% of all deaths are caused by cancer in these 
regions. According to the forecasts, cancer incidence 
will continue to rise from 14 mln in 2012 up to 22 mln in 
future decades [1]. 
In addition to irrecoverable losses of human lives, 
the high of cost oncological diseases contributes to the 
healthcare system not only in a direct financial term, 
but also in the form of indirect expenses, such as loss 
of production output due to the disability period 
(morbidity cost) and untimely death (mortality cost). 
Additional hidden cost can include transportation of 
patients, housekeeping cost and other supporting 
facilities [2]. Recent evidence suggest that comparing 
to other major causes of death, oncology diseases 
remains the most destructive impact on the world [3]. In 
a recent study by Harvard School of Public Health, 
researchers have counted that in 2010 the total 
financial cost of a 13.3 mln new registered cancer 
cases worldwide was around 290 billion (bln) United 
States Dollars (USD). The major part of the expenses 
(53%) consisted of a direct cost, while non-medical 
finances and costs associated with the  
 
 
*Address correspondence to this author at the Pharm-Sintez. LAB, Russia;  
Tel: +7 (903) 137-98-51; Fax: 8 (495) 7969434;  
E-mail: adrenoblocator@gmail.com 
disability-related time loss amounted around 67 bln 
USD and 69 USD bln respectively1. It is expected that 
by 2030 the total cost will grow up to 458 bln USD [4]. 
Along with that, according to the American Cancer 
Society and LIVESTRONG® estimates, excluding 
annual direct costs, oncology related economic losses 
will achieve up to 895 bln USD in the whole world [3]. It 
is remarkable that according to the social and 
economic study death is the most expensive process in 
the financial provision of the health care system, since 
financial costs by the end of the life amount to 12% of 
the whole medical provision budget, while 27% of the 
whole medical insurance budget1 is spent within the 
last 30 days of patient’s life [5]. 
Pharmacoeconomic (PhE) studies of radionuclide 
therapy for palliation of bone pain metastases are quite 
limited in the world. Moreover, most of the published 
PhE studies are performed using the “costs 
minimization” method, which is a very limited approach 
to the health care economics, as it is based only on 
cost comparison between different treatment methods. 
Some studies were carried out upon 89SrCl2 in the 90s 
[6-8] making it impossible to adapt the data to present 
time due to the rapid changes of the therapy regimens, 
appearance of modern effective methods of pain 
syndrome control, and other external factors.  
In a retrospective study researchers indicated a 
significant reduction of a total cost (by 5 696 $CAD) 
among patients with malignant neoplasm of prostate, 
who took 89SrCl2. It has been suggested that financial 
                                            
1 This context implies federal medical insurance program Medicare for the 
elderly population (over 65 years old) incorporated in the USA in 1965.  
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savings were associated with the reduction of a direct 
cost of radiation therapy (RT), as well as the cost 
associated with the services usage [6]. Furthermore, [7] 
reported similar direct costs reduction among patients 
with the metastatic hormone refractory prostate cancer 
(MHRPC). Based on research evidence, inclusion of 
89SrCl2 to the regimen of metastatic bone therapy 
allows to reduce costs for RT [7].  
The financial aspect of pharmaceutical pain 
management therapy for cancer patients can be quite 
considerable. Clinical experience established that most 
of the patients require significant doses escalation, 
which is related to disease progression and leads to 
addiction to analgesic agents. In another study 
researches showed that application of 89SrCl2 or 153Sm-
EDTMP allows to reduce the total cost of 
pharmacological pain-management therapy, thus 
reduce the total cost of the analgesic therapy [8]. 
Appropriate PhE analysis (for example, by “costs-
effectiveness”, “costs-utility” methods) seems to be 
quite difficult to accomplish, due to multiple economic 
variables related to the cost of Systemic Radionuclide 
Therapy (SRT)(delivery, synthesis of radiopharmaceu- 
tical, administration, monitoring, etc.), costs of the side 
effects therapy, organization and expenses saved 
during the SRT process. Reasonable cost for SRT can 
vary in different countries; for example, in the USA 
radionuclide therapy of painful bone metastases is 
estimated around 3 000-8 000 USD, in Korea – 2 400 
USD, in China – 100 USD, in Europe – 1000 USD [9].  
Other studies were performed in the 2000s, 
providing results of the pharmacoeconomic analysis 
carried out by “disease cost” [10] (2007), “costs-
effectiveness” (2005– [11], 2006 – [12])12 and “costs-
utility” (2012 - [13]) methods. 
It might be interesting to focus on the “disease cost” 
method carried out with SRT using 153Sm-EDTMP for 
patients (N=712) with MHRPC, accompanied by the 
pain syndrome. In this study, 85 patients (11,9%) were 
given 153Sm-EDTMP, 299 patients (42,1%) were given 
RT, 167 patients (6,6%) were given pamidronic acid, 
42 patients (6,6%) – Mitoxantronum and 119 (16,7%) – 
opioids. The therapy was carried out till the optimal 
                                            
2 Both studies are presented in the national languages, the first – in Spanish 
and the second – In Portugese, which considerably limits availability of the 
study results. 
control over the pain syndrome was reached for all 
patients. Additionally, all patients were followed-up for 
12 months after the therapy has started. Results 
showed no statistically significant difference between 
all groups in social-demographic features or prostatic 
specific antigen level (PSA). Opioid therapy appeared 
to be the most expensive method for the in-patient 
charge, comprising the largest portion of the expenses, 
while RT was the most expensive method for the out-
patient charge. Importantly the least expensive method 
both, in the in-patient and the out-patient charges, was 
the SRT СРТ153Sm-EDTMPR. Researchers recomm- 
end to consider SRT as a low-cost, effective and safe 
approach of pain syndrome management among 
patients with MHRPC [10]. 
Important to draw the attention to another study of 
the economic evaluation of 153Sm-EDTMP application 
in Canada. Despite that 153Sm-EDTMP was registered 
in Canada in 1997, clinical benefit of the drug has not 
been funded in any province. According to this study, 
the average cost of a conventional analgesic therapy 
for one patient was around 26 075 Canadian Dollars 
(CAD), while the total cost for all needing patients 
(n=539) was 14 054 425 CAD. The average cost of the 
analgesic therapy with 153Sm-EDTMP application for 
one patient was equal to 11 680 CAD, and the total 
costs for 539 patients was 6 295 520 CAD. By the time 
the article was prepared, the net cost of 153Sm-EDTMP 
was estimated of 4 500 CAD. With this price, the total 
cost for all scheduled SRTs (755 SRTs)1 with 
application of 153Sm-EDTMP in Canada will around 3 
397 500 CAD. Thus, the investments of a 3 397 500 
CAD into SRT by 153Sm-EDTMP for palliation therapy 
for patients with painful bone metastases, will lead to 
the economy of 7 758 905 CAD and realisation by the 
return of investment (ROI) will be equal to 228% [13]. 
The cost effectiveness analysis of 153Sm-EDTMP 
(Quadramet®) application for pain management among 
patients with prostate cancer and bone metastasis has 
previously been carried out [11]. To perform the 
analysis, researcher applied the “decision tree” model. 
Patients, who could not achieve an absolute pain 
control without conventional analgesic therapy were the 
potential candidates to start treatment with 153Sm-
EDTMP or they could continue the conventional 
therapy with dose escalation (time interval was 4 
months). The potential adverse effect of 
pharmacological therapy or necessity in the adjuvant 
therapy was also considered. Effectiveness data 
applied in the model was taken from the double blind 
clinical trial (N=152) among patients with MHRPC, 
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accompanied by the pain syndrome. The direct cost 
estimation was based on the cost of medical 
assistance3 according to SOIKOS (See Tables 1 and 
2). Prices for medical drugs were taken from the 
medical catalogue. The cost was expressed in Euro as 
for 2004. 
Present investigation displayed that from the costs-
                                            
3 Costs for medical assistance included radiation therapy, medication 
treatment and visits to the specialists, instrumental and laboratory 
examinations and in-patient stay. 
4 According to the specialists, consideration of accurate regimens is 
complicated by the explicit differences between the patients. In the 
whole, dose of opioids administered simultaneously with153Sm-
EDTMP was reduced by 20% in contrast to the conventional therapy, 
the exception was fentanyl therapy which remained unchanged. 
effectiveness point of view, the therapy by 153Sm-
EDTMP was a more reasonable and financially 
effective approach (see Table 3). Study findings and 
sensitivity analysis results indicated that the strategy 
with 153Sm-EDTMP application was the dominant one, 
i.e. it had the largest effectiveness and less cost for 
treatment than the conventional therapy5. 
However, it should be emphasized, that therapy 
regimens vary depending on the medical context, since 
pain is treated by different specialists and often is 
                                            
5 Except for the theoretical cases hardly possible in practice, which 
suggest that application of biphosphonates is equal to 0%, and pain 
intensity reduction against background of 153Sm-EDTMP continues 
for 2 months only. Increase of costs for on patient in such cases will 
amount to 630,04 € and 888,76 € respectively. 
Table1: Treatment Regimens Cost of Therapy by 153Sm-EDTMP 4 [11] 
 % Mean Value for 4 Months, Therapy Regimen  Cost, € 
Visits to doctors 
Pain management specialists 40 7 47.82 
Oncologist 60 7 47.32 
General practitioner 100 4 17.45 
Procedures 
Biochemical blood analysis, complete blood count 100 1 10.38 
Biochemical blood analysis, complete blood count (AE) 100 2 10.38 
Bone scanning 100 1.5 163.68 
Hospitalization 
Hospitalization (AE) 1.5 10 271.40 
Day patient department 100 1 149.74 
Medicines 
153Sm-EDTMP 100 - 466.01 
NSAIDs (one of the following)  
Ibuprofen 600 mg/8 h/4 months 
Diclofenac 50 mg /8 h/4 months 
Flurbiprofen 
100 
50 mg/8 h/4 months 
53.60 
Fentanyl (stripes) 15 600 µg /12 h/4 months 418.13 
Dexamethasone 12.5 2-3mg/8h/2 months 5.68 
Amitriptyline 12.5 25-75 mg /day/4 months 1.73 
Gabapentin 20 1.200-1.800 mg/day/ 4 months 64.63 
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determined by the level of medical center 
infrastructure. Treatment cost calculation is often based 
on the level of agreement between different medical 
expertise and specialists. Thus a mean value was 
considered, which possibly does not correspond to the 
actual data in a certain medical center, but rather 
reflects the average state of a medical practice in 
Spain. 
Table2: Treatment Regimens in the Conventional 
Therapy6 [11] 
 % 
Mean Value for 4 
Months, Therapy 
Regimen 
Cost, 
€ 
Visits to doctors 
Pain management 
specialists  33 7 47.82 
Pain management 
specialists (AE) 4 1.5 47.82 
Urologist 63.75 1 52.34 
Oncologist 95 6 47.32 
Oncologist (AE) 6 1.5 47.32 
General practitioner 100 4 17.45 
Procedures 
Biochemical blood 
analysis, complete 
blood count 
95 1.5 10.38 
Biochemical blood 
analysis, complete 
blood count (AE) 
10 1 10.38 
X-Ray study 25 1 16.56 
X-Ray study (due to 
the adjuvant therapy) 15 1 16.56 
X-Ray study of the 
abdominal cavity 
organs (AE) 
1 1 16.56 
Bone scan 100 1.5 163.68 
Radiation therapy 70 4-10 сеансов 23.35 
Hospitalization 
Hospitalization 5 15 271.4 
Hospitalization (AE) 6.5 6 271.4 
Day patient 
department 20 4 
149.7
4 
Medicines 
                                            
6 It shall be noted that therapy duration was 4 months not for all 
patients (which is determined by opioids rotation); it is demonstrated 
in the table in the form of percent from the total patient’s number, 
who were given therapy, on condition that all the patients were given 
any type of opioids within the described time period. 
NSAIDs (one of the following)  
Ibuprofen 600 mg/8h/4months 
Diclofenac 50 mg/8h/4months 
Flurbiprofen 
100 
50 mg/8h/4months 
53.60 
Metamizol 20 500 mg/6h/4months 11.18 
Fentanyl (stripes) 15 600 µg/12h/4months 418.13 
Fentanyl (patches) 32.5 100-200mg/3days/4months 67.29 
Peroral morphine 50  120-400mg/day/4 months 
170.3
8 
Injection morphine 10  40-150mg/day/4 months 43.82 
Morphine via 
individual catheter 3.5 8 mg/day epidurally 15.53 
Methadone 10 20 mg/day/4 months 11.68 
Lactulose 90 30 mg/day/4 months 59.19 
Metoclopramide 1  60 mg/day/4 months 0.26 
Dexamethasone 12.5  2-3mg/8h/2months 5.68 
Amitriptyline 12.5  25-75mg/day/4 months 1.73 
Gabapentin 20  1200-1800 mg/day/ 4 months 64.63 
Zoledronic acid 20  4 mg/4weeks/4months 252.48 
 
In respect to the final results of the study, the main 
conclusion implies that 153Sm-EDTMP is a cost-
effective and efficient method of pain management for 
patients with MHRPC and bone metastases. Moreover, 
it shall be specified that 153Sm-EDTMP is highly 
effective for all patients with metastatic pains, 
regardless of their origin, in case when such 
metastases are discovered during a routine bone 
scanning. 
Therefore, in recent 20 years only 7 studies were 
published on pharmacoeconomic study of the 
skeleton’s radionuclide therapy, despite a wide spread 
application of this technology in clinical practice in the 
whole world. 
It should be noted that a new radiopharmaceutical 
228Ra is designed for castration-resistant prostate 
cancer with symptomatic bone but without visceral 
metastases, has a different to 153Sm, 188Re and 186Re 
clinical indications. Despite of that there is The National 
Centre for Pharmacoeconomics (NCPE) publication 
related to the 228Ra that presents the cost-effective 
analysis of 228Ra vs. best supportive therapy (based on 
the overall trial population data), 228Ra versus 
abiraterone (based on post-docetaxel population trial 
data but following NCPE assessment of the company 
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submission, the NCPE considers that the cost 
effectiveness of 228Ra has not been demonstrated [14]. 
In 2016 The Global Journal of Health Science 
documented several studies reporting data on the use 
of radium-223 (which is an alpha-emitting radioisotope 
that targets areas of osteoblastic metastasis and is 
Food and Drug Administration (FDA) approved) for 
treating mCRPC from the point of pharmacoeconomics 
review [15] by NCPE [14], The Ludwig Boltzmann 
Institute, NICE, German Institute for Quality and 
Efficiency in Health Care (IQWiG), Aberdeen HTA 
group (National Institute of Health Research (NIHR) 
and Swedish National Board for Health and Welfare. 
As authors mentioned in the review “studies reporting 
any figures on the cost-effectiveness of this therapy 
were generally of a low quality. Most guidelines did not 
include any economic considerations when giving their 
state of art. When cost was mentioned, the guidelines 
gently touched the item by mentioning there are costs” 
[15]. Consequently, 223Ra-therapy is a not cost-
effective approach and there is an insufficient data for 
final conclusions. Thus, there is a very limited support 
for health care administrators because of it’s price. 
Recently researchers have been interested in 177Lu-
labeled ethylenediamine tetramethylene phosphonic 
acid (177Lu-EDTMP), which is an agent that 
concentrates in areas of enhanced osteoblastic activity. 
Some studies show that 177Lu-EDTMP could be used 
as an effective therapeutic radionuclide for palliation of 
metastatic bone pain [16]. Moreover, Lutetium-177 has 
favourable characteristics, such as low energy β− 
emission, which should reduce the toxicity. Preliminary 
studies have already confirmed selective tracer 
accumulation in the skeletal lesions [16]. However, the 
number of clinical trials is very limited. Moreover, most 
of the studies are underpowered due to the insufficient 
number of participants, as well as lack of a 
randomization and alternative treatment arm. 
Moreover, there are no evidence of the financial 
advantages of 177Lu-EDTMP over other agents. Thus, it 
is impossible to conduct a cost-effective analysis. The 
work is still ongoing and further investigation of the 
177Lu-EDTMP effectiveness for the palliation therapy of 
metastatic bone pain and it’s financial cost during the 
therapeutic course is required as well as it's financial 
implication in treatment strategy.  
Currently there is a rapid development of other 
radiopharmaceutical agents that apply generator-
produced isotope, such as 188Re-zoledronic acid and 
are designed for the skeleton’s metastatic lesions 
therapy. It should be expected, that due to the 
availability of 188Re generators, as well as the 
convenience of 188Re receipt directly in the ward, there 
will be a reduction of the net cost of 
radiopharmaceutical agent’s production along with the 
increase of therapeutic performance and reduction of 
side effects. However, the data about the cost of 
radiopharmaceutical agent’s production on the basis of 
188Re is limited. Therefore, in order to conduct a 
comprehensive evaluation of the technologies based 
on 188Re, valid pharmacoeconomic studies should be 
conducted in nearest future. 
CONCLUSION 
Today, the field of radionuclide diagnostic and 
therapy is going through an extremely interesting 
phase. Recent significant technological advances make 
it very likely that radiopharmaceuticals will become an 
important part of diagnostic and therapy of various 
forms of cancer. Despite that the potential of 
radionuclides in treatment has been recognised a while 
ago, the area is strongly underinvestigated. Most of 
studies are performed locally with small amount of 
participants, which makes them statistically 
underpowered. As a results it is impossible to perform 
a valid pharmacoeconomic evaluation and analysis, 
which in fact prevents application of a nuclear 
medicine’s methods to clinical practice. Thus, in order 
to continue research and create an optimal therapeutic 
and financial strategy for patients, industry calls for 
further investments.  
Table 3: Results of the Pharmacoeconomic Effectiveness Analysis 
 Conventional Therapy, € Therapy by 153Sm-EDTMP, € Incremental “Cost-Effectiveness”Ratio 
Direct costs 2 252.77 2 126.30 
Complete response 18 38 
Costs for the patient 12 515.39 5 595.52 
153Sm-EDTMP – dominant 
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